120 related articles for article (PubMed ID: 25268071)
21. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
22. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
[TBL] [Abstract][Full Text] [Related]
23. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.
Hong DS; Vence L; Falchook G; Radvanyi LG; Liu C; Goodman V; Legos JJ; Blackman S; Scarmadio A; Kurzrock R; Lizee G; Hwu P
Clin Cancer Res; 2012 Apr; 18(8):2326-35. PubMed ID: 22355009
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutation testing in clinical practice.
Ziai J; Hui P
Expert Rev Mol Diagn; 2012 Mar; 12(2):127-38. PubMed ID: 22369373
[TBL] [Abstract][Full Text] [Related]
25. BRAF--a new player in hematological neoplasms.
Machnicki MM; Stoklosa T
Blood Cells Mol Dis; 2014; 53(1-2):77-83. PubMed ID: 24495477
[TBL] [Abstract][Full Text] [Related]
26. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.
Hussain F; Horbinski CM; Chmura SJ; Yamini B; Lukas RV
Neurologist; 2018 Sep; 23(5):163-166. PubMed ID: 30169370
[TBL] [Abstract][Full Text] [Related]
27. Melanocytomas of the central nervous system: a clinicopathological and molecular study.
Wang H; Zhang S; Wu C; Zhang Z; Qin T
Eur J Clin Invest; 2013 Aug; 43(8):809-15. PubMed ID: 23683178
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
Sclafani F; Gullo G; Sheahan K; Crown J
Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
[TBL] [Abstract][Full Text] [Related]
29. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
30. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.
Rutkowski P; Blank C
Expert Opin Drug Saf; 2014 Sep; 13(9):1249-58. PubMed ID: 25014231
[TBL] [Abstract][Full Text] [Related]
31. Molecular predictors of outcome in low-grade glioma.
Weiler M; Wick W
Curr Opin Neurol; 2012 Dec; 25(6):767-73. PubMed ID: 23160425
[TBL] [Abstract][Full Text] [Related]
32. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
33. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
34. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
35. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults.
Hasselblatt M; Riesmeier B; Lechtape B; Brentrup A; Stummer W; Albert FK; Sepehrnia A; Ebel H; Gerss J; Paulus W
Neuropathol Appl Neurobiol; 2011 Dec; 37(7):803-6. PubMed ID: 21696415
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic BRAF Alterations and Their Role in Brain Tumors.
Behling F; Schittenhelm J
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181803
[TBL] [Abstract][Full Text] [Related]
37. Targeted Therapies in Rare Brain Tumours.
Bruno F; Pellerino A; Bertero L; Soffietti R; Rudà R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360713
[TBL] [Abstract][Full Text] [Related]
38. Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data.
Stichel D; Schrimpf D; Sievers P; Reinhardt A; Suwala AK; Sill M; Reuss DE; Korshunov A; Casalini BM; Sommerkamp AC; Ecker J; Selt F; Sturm D; Gnekow A; Koch A; Simon M; Hernáiz Driever P; Schüller U; Capper D; van Tilburg CM; Witt O; Milde T; Pfister SM; Jones DTW; von Deimling A; Sahm F; Wefers AK
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):406-414. PubMed ID: 33336421
[TBL] [Abstract][Full Text] [Related]
39.
Srinivasa K; Cross KA; Dahiya S
Front Oncol; 2020; 10():574974. PubMed ID: 33042847
[No Abstract] [Full Text] [Related]
40. The diagnostic role and clinical relevance of determination of BRAF status in brain tumors.
Gessi M; Pietsch T
Per Med; 2013 Jun; 10(4):405-412. PubMed ID: 29783415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
